Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics


Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): $8.18

-0.73 (-8.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AVDL Stock Price Chart Interactive Chart >

Price chart for AVDL

AVDL Price/Volume Stats

Current price $8.18 52-week high $10.20
Prev. close $8.91 52-week low $1.05
Day low $8.00 Volume 578,600
Day high $9.00 Avg. volume 455,132
50-day MA $8.16 Dividend yield N/A
200-day MA $6.36 Market Cap 505.35M

Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) Company Bio


Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products based on its proprietary drug delivery technology for primary care and sterile injectable markets in the United States, France, and Ireland. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. The company was founded in 1990 and is based in Dublin, Ireland.


AVDL Latest News Stream


Event/Time News Detail
Loading, please wait...

AVDL Latest Social Stream


Loading social stream, please wait...

View Full AVDL Social Stream

Latest AVDL News From Around the Web

Below are the latest news stories about AVADEL PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate AVDL as an investment opportunity.

Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension

- Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. This s

Yahoo | March 2, 2023

Avadel Pharmaceuticals Shows Big Promise -- And Risk

Here's how I'd play the stock of this small-cap whose narcolepsy drug recently received good news.

Yahoo | February 28, 2023

UPDATE 2-Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug

A U.S. appeals court ordered Jazz Pharmaceuticals Inc on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc. The decision by the U.S. Court of Appeals for the Federal Circuit removes an obstacle for Avadel to sell its own narcolepsy drug Lumryz. Avadel stock was up 4.2% Friday afternoon following the ruling, and Jazz stock was down 1.4%.

Yahoo | February 24, 2023

Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug

A U.S. appeals court ordered Jazz Pharmaceuticals Inc on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc. The decision by the U.S. Court of Appeals for the Federal Circuit removes an obstacle for Avadel to sell its own narcolepsy drug Lumryz. Avadel stock was up 4.2% Friday afternoon following the ruling, and Jazz stock was down 1.4%.

Yahoo | February 24, 2023

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 28,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employees’ acceptance of employment with Avadel i

Yahoo | February 16, 2023

Read More 'AVDL' Stories Here

AVDL Price Returns

1-mo -2.39%
3-mo 20.29%
6-mo 63.27%
1-year 16.52%
3-year 34.32%
5-year 14.41%
YTD 14.25%
2022 -11.39%
2021 20.96%
2020 -11.52%
2019 192.64%
2018 -68.54%

Continue Researching AVDL

Want to see what other sources are saying about Avadel Pharmaceuticals Plc's financials and stock price? Try the links below:

Avadel Pharmaceuticals Plc (AVDL) Stock Price | Nasdaq
Avadel Pharmaceuticals Plc (AVDL) Stock Quote, History and News - Yahoo Finance
Avadel Pharmaceuticals Plc (AVDL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9096 seconds.